display technology ensures proper conformation of multi-transmembrane proteins while enhancing their immunogenicity. KACTUS also provides research and GMP-grade tools for genetic modification, ...

Researchers at Novartis BioMedical Research in the US and Switzerland have identified a molecular target that may provide a ...

Some outside researchers were less reserved. Clinical trials using CRISPR gene editing have been underway for nearly a decade. But like most trials, they focused on broad groups of patients.

A baby boy with a devastating genetic disease is thriving after becoming the first known person to receive a bespoke, CRISPR therapy-for-one, designed to correct his specific disease-causing ...

Powertips' latest display innovation available from Inelco Hunter Credit: Inelco Hunter The 4.3-inch IPS model has been designed for a wide range of embedded applications and features resolution of ...

A US court just put ownership of CRISPR back in play The CRISPR patents are back in play. Yesterday, the US Court of Appeals for the Federal Circuit said scientists Jennifer Doudna and Emmanuelle ...

CRISPR Therapeutics has begun realizing sales on Casgevy, its first therapy and a joint venture with Vertex Pharmaceuticals. The company has plenty of cash to fund research and development for the ...

In the latest market close, CRISPR Therapeutics AG (CRSP) reached $39.11, with a +1.48% movement compared to the previous day. This move lagged the S&P 500's daily gain of 2.03%. At the same time ...

G ene therapy has always held enormous promise to correct genetic diseases, but turning that potential into treatments has ...

Gene therapy developer CRISPR Therapeutics AG (CRSP) is navigating some regulatory and commercial dynamics. Its flagship gene therapy product for treating sickle cell disease, Casgevy, faces ...